
Opinion|Videos|February 1, 2025
One Institution’s Evidence-Based Approach to Adopting Biosimilars
A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please describe the process your institution uses to review biosimilars as potential additions to the formulary.
- What priorities were identified by your institution for the purposes of operationalizing the use of biosimilars?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
What exactly is managed care today?
3
TrumpRx launches; some experts question its long-term value
4
PBM reform. It has finally happened
5






















